Department of Clinical Pharmacy, State Key Laboratory of Analytical Chemistry for Life Science & Jiangsu Key Laboratory of Molecular Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210002, China.
China Pharmaceutical University, Nanjing, 210009, Jiangsu Province, China.
Bioanalysis. 2024;16(17-18):973-984. doi: 10.1080/17576180.2024.2383109. Epub 2024 Aug 14.
Differences are existed in the bioactivity among various vitamin K (VK) forms. To investigate the correlation between clinical parameters of initial anticoagulation and plasma levels of VK1 and VK2 (MK-4 and MK-7), it was necessary to establish a quantitative method for simultaneous determination. Plasma samples in cardiovascular patients were extracted by cyclohexane and analyzed using a C18 column. Baseline concentrations of VK1, MK-4 and MK-7 were 0.98 ± 0.52 ng/ml, 0.45 ± 0.13 ng/ml and 0.65 ± 0.31 ng/ml, respectively. The concentrations of MK-7 and total VKs were significantly relevant to INR0, respectively (p = 0.010 and p = 0.048, respectively). Thus, when adjusting anticoagulation dosage, concentrations of various VK homologues might be considered.
各种维生素 K（VK）形式的生物活性存在差异。为了研究初始抗凝治疗的临床参数与 VK1 和 VK2（MK-4 和 MK-7）的血浆水平之间的相关性，有必要建立一种同时定量测定的方法。用环己烷提取心血管病患者的血浆样本，并使用 C18 柱进行分析。VK1、MK-4 和 MK-7 的基线浓度分别为 0.98±0.52ng/ml、0.45±0.13ng/ml 和 0.65±0.31ng/ml。MK-7 和总 VKs 的浓度分别与 INR0 显著相关（p=0.010 和 p=0.048）。因此，在调整抗凝剂量时，可能需要考虑各种 VK 同系物的浓度。
